TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03665493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=1.5-2 Medications ON
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=1.5-2 Medications OFF
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy age-matched controls
Description: Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=3 Medications OFF
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD patients H&Y=3 Medications ON
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Study: NCT01910779

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 100 joule as first biphasic shock energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 120 joule as first biphasic shock energy
Study: NCT04159935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux® system
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux® system
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
Study: NCT03848637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-375
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-375
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D387
Description: Reference drug
Study: NCT00492895

Intervention type: DRUG
Group type: OTHER
Intervention: Discontinuation of Azathioprin
Description: Discontinuation of Azathioprin
Study: NCT03850210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Splint
Description: Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Long Splint
Description: Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
Study: NCT02094729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAN2401 2.5 mg/kg
Description: Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAN2401 5 mg/kg
Description: Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
Study: NCT02259881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIBT 986 CL, per i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIBT 986 CL, per i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIBT 986 CL, per i.v. infusion
Study: NCT02094729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAN2401 10 mg/kg
Description: Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusions of placebo for 60 +/- 10 minutes.
Study: NCT02283346

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy + hypofractionated EBRT
Description: Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints).
Study: NCT04557995

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erythropheresis
Description: Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
Study: NCT01788111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low back exercises 1
Description: Excentric / concentric extension type exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low back exercise 2
Description: Traditional low back training
Study: NCT04359121

Intervention type: OTHER
Intervention: Questionnaires for specific phobia
Description: Questionnaires will be used.

Intervention type: OTHER
Intervention: Questionnaires for specific phobia
Description: Questionnaires will be used.

Intervention type: OTHER
Intervention: Questionnaires for specific phobia
Description: Questionnaires will be used.

Intervention type: OTHER
Intervention: Questionnaires for specific phobia
Description: Questionnaires will be used.
Study: NCT02683707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removal of Fentanyl from peri-procedural analgesia
Description: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV peri-procedural analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local Anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Local Anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: IV sedation
Study: NCT02393222

Intervention type: OTHER
Intervention: Observing effect of routine HD
Description: Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
Study: NCT00836303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorecatal Cancer Screening Activation
Description: Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
Study: NCT04263415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-weekly injection with placebo pen for 16 weeks
Study: NCT03848637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D387
Description: Reference drug
Study: NCT01955837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study: NCT05268068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study: NCT03953989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die
Description: Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
Study: NCT05268835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalacin C
Description: The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
Study: NCT04520178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan 100 MG
Description: 100mg combined with 50mg carbidopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Hydroxytryptophan
Description: 50mg combined with 50mg carbidopa

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Carbidopa
Description: 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa
Description: 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa
Description: 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03716687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic negative pressure wound dressing after laparotomy
Description: Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
Study: NCT02259881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS), single i.v. bolus
Description: Endotoxin derived from E. coli bacteria, used for activation of coagulation
Study: NCT01159821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 31001074/paroxetine
Description: 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
Study: NCT06152692

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SHAM Continuous positive airway pressure
Description: Placebo treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
Study: NCT01285752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK106-001616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK106-001616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Study: NCT04307953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530 Difumarate
Description: AZD0530 for the duration of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo during 6 month RCT, AZD0530 thereafter
Study: NCT02259881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS), single i.v. bolus
Description: Endotoxin derived from E. coli bacteria, used for activation of coagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS), single i.v. bolus
Description: Endotoxin derived from E. coli bacteria, used for activation of coagulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide (LPS), single i.v. bolus
Description: Endotoxin derived from E. coli bacteria, used for activation of coagulation
Study: NCT03622944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technic
Description: post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Friction Massage
Description: deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
Study: NCT03622944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: spinal stabilization exercise were applied three sessions in a week totally six weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: spinal stabilization exercise were applied three sessions in a week totally six weeks.
Study: NCT03281369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
Study: NCT00920946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 20 mg Dimebon orally TID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally TID
Study: NCT00524667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid & fludarabine
Description: valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
Study: NCT01061645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOC31-PE
Description: Immunotoxines
Study: NCT04377789

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin Prophylaxis
Description: a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin Treatment
Description: a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
Study: NCT01510548

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab injections for acute disc prolapse patients
Description: see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab injections for acute disc prolapse patients
Description: see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab injections for acute disc prolapse patients
Description: see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
Study: NCT02509299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program 1
Description: The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program 2
Description: COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises

Intervention type: DRUG
Group type: OTHER
Intervention: Standard medical treatment
Description: The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Study: NCT00889369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
Study: NCT01531829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Description: Low dose (50mg/2h) rt-PA plus LMWH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin
Description: 0.1ml/10kg,q12h,5-7 days
Study: NCT03788304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive ventilation
Description: conventional NIV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: HFNC ventilation
Study: NCT00737750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab
Description: Program of NMES 3 times per day, five days per week for 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poli-Stim
Description: Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Voluntary quadriceps muscle contractions.
Study: NCT00637650

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment
Study: NCT05393843

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids, anthocyanins and alpha-cyclodextrins
Description: administration for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: 12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: diet
Description: 12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
Study: NCT01546376

Intervention type: RADIATION
Intervention: Radiation therapy
Description: External photon beam radiation therapy dosage 4000-7000 CGy

Intervention type: OTHER
Intervention: Venepuncture
Description: Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
Study: NCT04275206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harkány medicinal water
Description: The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tap water (placebo control)
Description: The control group is treated with tap water.
Study: NCT04289597

Intervention type: DIAGNOSTIC_TEST
Intervention: Distance between hyoid bone-skin (DSHB)
Description: Distance between hyoid bone-skin

Intervention type: DIAGNOSTIC_TEST
Intervention: Vocal cord anterior commissura-skin distance (DSAC)
Description: Vocal cord anterior commissura-skin distance

Intervention type: DIAGNOSTIC_TEST
Intervention: minimum distance of the trachea to the skin at the level of suprasternal notch
Description: Distance of the trachea to the skin at the level of suprasternal notch

Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid isthmus-skin distance (DSI)
Description: Thyroid isthmus-skin distance

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin-epiglottic distance (DSE)
Description: Skin-epiglottic distance